Literature DB >> 15913506

Coronary No-reflow Phenomenon.

Shereif H Rezkalla1, Robert A Kloner.   

Abstract

No-reflow occurs in up to one third of patients with acute myocardial infarction during acute percutaneous intervention, and occasionally during elective interventions, particularly vein graft intervention. Multiple intracoronary medications will restore flow in most cases. We begin with 100 to 1000 mg of nitroprusside, verapamil, or adenosine at a similar dosage. We give it at 100-mg increments at high velocity. We inject it distally in the epicardial artery to avoid any systemic effect, and we do it through an intracoronary perfusion catheter. At times, we use prophylactic injections (prior to balloon inflation), particularly in vein graft intervention. Most of these strategies are not formally approved for treating no-reflow. However, reversing this condition with restoration of normal coronary flow is essential for an improved left ventricular function and a better cardiac outcome.

Entities:  

Year:  2005        PMID: 15913506     DOI: 10.1007/s11936-005-0008-0

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  42 in total

1.  Refractory no-reflow successfully treated with local infusion of high-dose adenosine and verapamil--a case report.

Authors:  W C Dillon; D Hadian; M E Ritchie
Journal:  Angiology       Date:  2001-02       Impact factor: 3.619

2.  Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine.

Authors:  T A Fischell; A J Carter; M T Foster; K Hempsall; J DeVries; D H Kim; A Kloostra
Journal:  Cathet Cardiovasc Diagn       Date:  1998-12

3.  Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.

Authors:  W B Hillegass; N A Dean; L Liao; R G Rhinehart; P R Myers
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

4.  Clinical and postmortem outcome of "no-reflow' phenomenon in a patient treated with rotational atherectomy.

Authors:  M Bowles; W Palko; C Beaver; C Cowley; R Kipperman
Journal:  South Med J       Date:  1996-08       Impact factor: 0.954

5.  Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Authors:  James E Tcheng; David E Kandzari; Cindy L Grines; David A Cox; Mark B Effron; Eulogio Garcia; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; Martin Fahy; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  Circulation       Date:  2003-08-25       Impact factor: 29.690

6.  Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention.

Authors:  Jeffrey J Popma; Nicholas Cox; K Eugene Hauptmann; Nicolaus Reifart; Renu Virmani; Khaled Emira; Sabina Murphy; C Michael Gibson; Eberhard Grube
Journal:  Catheter Cardiovasc Interv       Date:  2002-10       Impact factor: 2.692

7.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

Authors:  R A Kloner; C E Ganote; R B Jennings
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

Review 8.  Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications.

Authors:  S Iliceto; V Marangelli; A Marchese; A Amico; L Galiuto; P Rizzon
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

9.  Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty.

Authors:  I Morishima; T Sone; S Mokuno; S Taga; A Shimauchi; Y Oki; J Kondo; H Tsuboi; H Sassa
Journal:  Am Heart J       Date:  1995-08       Impact factor: 4.749

10.  Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up.

Authors:  M D Kenner; E J Zajac; G T Kondos; R Dave; J W Winkelmann; J Joftus; A Laucevicius; A Kybarskis; E Berukstis; A Urbonas
Journal:  Am J Cardiol       Date:  1995-11-01       Impact factor: 2.778

View more
  2 in total

1.  Intracoronary adenosine versus intravenous adenosine during primary PCI for ST-elevation myocardial infarction: which one offers better outcomes in terms of microvascular obstruction?

Authors:  Gemina Doolub; Erica Dall'armellina
Journal:  ISRN Cardiol       Date:  2013-03-27

2.  Relation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention.

Authors:  Barış Yaylak; Bernas Altıntaş; Kazım Serhan Özcan; Evliya Akdeniz; İlker Avcı; Gönül Zeren; Barış Şimşek; Can Yücel Karabay
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-12-11       Impact factor: 1.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.